Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Equity

v3.26.1
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period (in shares) at Mar. 31, 2023   33,508,076              
Balance, beginning of period at Mar. 31, 2023 $ 418,988 $ 33 $ 239,860 $ 0 $ 237,195 $ (58,100)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             22,829 98,177 101,161
Stock compensation expense 5,754   5,754            
Repurchase of employee stock units on vesting (2,058)   (2,058)            
Repurchase of shares under authorized program (in shares)   (8,018)              
Repurchase of shares under authorized program (250)     (250)          
Net income 51,588       51,588        
Foreign currency translation adjustment 836         836      
Other 29 $ 1 (1)     29      
Balance, end of period (in shares) at Mar. 31, 2024   33,722,225              
Balance, end of period at Mar. 31, 2024 474,887 $ 34 243,555 (250) 288,783 (57,235)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in exercise of stock options (in shares)   33,573              
Issuance of common stock in exercise of stock options 632   632            
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             21,802 72,013 87,782
Stock compensation expense 5,244   5,244            
Repurchase of employee stock units on vesting $ (3,230)   (3,230)            
Repurchase of shares under authorized program (in shares) (694,025) (694,025)              
Repurchase of shares under authorized program $ (20,138)     (20,138)          
Net income 53,515       53,515        
Foreign currency translation adjustment (15,515)         (15,515)      
Other $ (80) $ (1)       (79)      
Balance, end of period (in shares) at Mar. 31, 2025 33,243,370 33,243,370              
Balance, end of period at Mar. 31, 2025 $ 495,315 $ 33 246,201 (20,388) 342,298 (72,829)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of common stock in exercise of stock options (in shares) 5,074 5,074              
Issuance of common stock in exercise of stock options $ 72   72            
Issuance of restricted stock as deferred compensation to directors, employees and executive officers (in shares)             22,851 90,952 105,230
Stock compensation expense 8,244   8,244            
Repurchase of employee stock units on vesting $ (3,732)   (3,732)            
Repurchase of shares under authorized program (in shares) (601,125) (601,125)              
Repurchase of shares under authorized program $ (15,774)     (15,774)          
Net income 44,571       44,571        
Foreign currency translation adjustment 10,011         10,011      
Other $ 0         0      
Balance, end of period (in shares) at Mar. 31, 2026 32,866,352 32,866,352              
Balance, end of period at Mar. 31, 2026 $ 538,707 $ 33 $ 250,785 $ (36,162) $ 386,869 $ (62,818)